Orasure Earnings Call: Margin Gains Amid Costly Turnaround

Orasure ((OSUR)) has held its Q4 earnings call. Read on for the main highlights of the call.

Orasure’s latest earnings call struck a tone of cautious optimism, as management pointed to a modest revenue beat, improving gross margins, and a fortress-like balance sheet with no debt. Yet executives were equally clear that sizable operating losses, underused manufacturing capacity, and a multi‑year path back to cash‑flow breakeven leave little room for execution missteps.

Revenue Beat Highlights Resilient Core Business

Total revenue in Q4 2025 reached $26.8 million, with core revenue excluding COVID at $26.7 million, landing above the midpoint of guidance and signaling stabilization in the underlying business. While the absolute level remains modest, investors watching for post‑pandemic normalization will see this as evidence that the core franchise is starting to regain its footing.

Segment Performance Tracks Expectations

Diagnostic Products delivered $15.1 million in Q4 revenue and Sample Management Solutions contributed $9.1 million, both roughly in line with internal expectations. The performance suggests the company is holding share in key niches rather than relying on one‑off spikes, a necessary base for the more ambitious growth catalysts coming in the next two years.

Gross Margin Recovery Gains Traction

Profitability metrics showed meaningful progress, with GAAP gross margin improving to 41.0% in Q4 2025 from 36.2% a year earlier and non‑GAAP gross margin rising to 41.4% from 40.1%. Management attributes the improvement to manufacturing consolidation and better mix, and indicated that incremental gains should continue as volumes increase and fixed costs are better absorbed.

Balance Sheet Strength and Capital Return

Orasure closed the year with $199 million in cash and cash equivalents and zero debt, providing flexibility to weather operating losses and fund product launches. The company also returned capital to shareholders, repurchasing $5 million of stock in Q4 and $15 million in 2025 overall, signaling confidence in long‑term value despite near‑term red ink.

New FDA Submissions Target Large STI Market

A major focus of the call was two FDA submissions made in December, including Sherlock CT/NG, an over‑the‑counter rapid molecular self‑test for chlamydia and gonorrhea, and the Colli‑Pee at‑home urine collection device for STIs. Management is aiming for midyear launches and a revenue ramp in the second half of 2026, noting that the CT/NG market alone is estimated to exceed $1.5 billion.

International Expansion and Nearshoring Strategy

International growth initiatives are beginning to take shape, highlighted by the Canadian launch of the OraQuick HIV Self‑Test as the first oral HIV self‑test licensed in that market. Order patterns in broader international diagnostics are stabilizing, and nearshoring moves in Africa, including local assembly and manufacturing, are expected to start contributing revenue in the first quarter of 2026.

BiMedomics Integration and Sickle Cell Opportunity

The roughly $4 million acquisition of BiMedomics is off to a promising start, with strong demand reported for the Sickle SCAN sickle cell test. Orasure plans to leverage its existing channels in Africa and Latin America to scale this product, positioning the acquisition as both a growth vehicle and a way to deepen the company’s footprint in high‑need regions.

Operational Efficiencies and Manufacturing Consolidation

Management emphasized that major manufacturing consolidation is largely complete, with volumes moved into the Bethlehem facility and about 95–97% of previously outsourced sample management now handled internally. This footprint sets the stage for better overhead absorption as volumes grow and supports expectations for Q1 2026 gross margins to remain in the low‑40% range with modest sequential improvement.

Persistent Operating Losses and Cash Burn

Despite improving margins, the company posted a GAAP operating loss of $20.1 million and a non‑GAAP operating loss of $15.2 million in Q4 2025, with operating cash flow negative $9 million. Management laid out a multi‑year plan to reach operating cash‑flow breakeven by 2027, underscoring that the turnaround will require sustained revenue growth and disciplined cost control.

Elevated Operating Expenses and R&D Trajectory

Operating expenses remain high, with Q4 R&D at $11.4 million, sales and marketing at $6.6 million, and G&A at $9.8 million, reflecting ongoing clinical trials and commercial investments. The company expects R&D to trend lower over full‑year 2026 but cautioned that trial‑related costs will persist early in the year as key programs move toward commercialization.

Funding Disruptions Weigh on International HIV Sales

Management noted that 2025 was marked by a difficult funding backdrop, including implementation issues tied to major international HIV programs, which disrupted ordering patterns and forced countries to rethink budget and rollout plans. While recovery is underway, management stressed that timing remains uneven across markets, adding another layer of uncertainty to the near‑term revenue trajectory.

Regulatory and Capacity Constraints Shape Risk Profile

The team acknowledged that regulatory review timelines for the new products are inherently uncertain, and delays could push the anticipated second‑half 2026 ramp further out. Compounding the risk, the company is currently running operations at about 30% capacity, meaning margins will rely heavily on successfully scaling revenue to better utilize its fixed cost base.

Restructuring Costs Temper Near‑Term Profitability

To streamline operations, Orasure has reduced headcount in nonproduction roles and incurred one‑time severance and restructuring charges that weighed on recent results. While these moves are intended to improve efficiency over time, they partially offset the margin benefits from consolidation in the near term and highlight the balancing act between cost cuts and growth investment.

Guidance and Outlook Emphasize Gradual Improvement

For the first quarter, Orasure guided revenue between $26 million and $29 million with negligible COVID contributions and gross margins in the low‑40% range, slightly ahead of Q4 levels. Management reiterated its 2027 target for operating cash‑flow breakeven, expects R&D to decline over 2026, and continues to plan for a midyear regulatory timeline with a meaningful revenue ramp from new products anticipated in the second half of 2026.

Orasure’s earnings call painted a picture of a company in transition, anchored by a strong balance sheet and emerging product catalysts but still wrestling with losses and uneven demand. For investors, the story hinges on whether management can convert regulatory wins and international expansion into a sustained top‑line recovery that fully unlocks the margin and cash‑flow potential embedded in its underused manufacturing base.